Bilal Salman։ NETosis as a Therapeutic Target in Inflammation and Thrombosis
Bilal Salman, Student at University of Balamand, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in European Journal of Inflammation, adding:
”Neutrophil extracellular traps (NETs) are increasingly recognized as important mediators linking innate immunity, inflammation, thrombosis, and cardiovascular remodeling.
These figures from our most recent publication highlight potential therapeutic targets involved in ROS generation (Apocynin, DPI, Colchicine, Thiocyanate, Selenocyanate), ROS clearance (GSH + NAC), NET formation (GSK), NET clearance (DNase I), as well as immunomodulatory therapies (Anakinra, IL-1 monoclonal antibody, and anti-IL6R therapy).
Targeting ROS may reduce the signals that initiate NETosis. Targeting PAD4 may prevent NET formation directly, while DNase I can help remove NETs after they have formed. Immunomodulators such as anakinra, IL-1β blockade, and anti-IL-6R therapy instead target the inflammatory environment surrounding NETosis.
The major challenge is finding the right balance between suppressing pathological NETosis and preserving the essential antimicrobial functions of neutrophils.
NETosis therefore represents a fascinating therapeutic intersection between oxidative stress, innate immunity, inflammation, thrombosis, and cardiovascular disease.”
Title: Role of neutrophil extracellular traps in myocardial infarction pathogenesis, diagnosis, and treatment
Authors: Lea Aridi, Bilal Salman, Layan Ghraizi, Daniel Mhanna, Rima Haidar, Bernard Harbieh, Ghassan Nabbout, Frederic Harb, Sami Azar, Hilda E. Ghadieh
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 15:58Bernhard Merget: New Frontiers in Thrombosis and Stroke Research
-
Sep 30, 2026, 15:39Ifeanyichukwu Ifechidere: The Molecular Orchestra of Primary Hemostasis
-
Sep 30, 2026, 15:28Reassessing the Benefit–Risk Balance of Extended Anticoagulation in Cancer Patients – ESC Working Group on Cardiovascular Pharmacotherapy
-
Sep 30, 2026, 15:07Chiranjeev Sharma: Targeting Factor XIa with the Synthetic Inhibitor SB-01
-
Sep 30, 2026, 14:41Bruna Gigante: Balancing Thrombosis and Bleeding in Cardiovascular Care
-
Sep 30, 2026, 14:13Ashok Choudhury: Portal Vein Thrombosis and Outcomes in Cirrhosis
-
Sep 30, 2026, 13:57Leslye Conde Bazán: When Conventional Imaging Is Not Enough – The Role of IVUS
-
Sep 30, 2026, 13:41Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?